The late-stage drug is intended to serve as a long-term treatment for airflow obstruction in COPD patients. Sunovion did not share the FDA’s reason for rejecting the drug, but said the agency is not requiring the company to conduct additional clinical trials before reapplying for the drug’s approval.
“Sunovion will work with the FDA to determine an appropriate path forward,” the company said in a news release. “We are confident in [the drug] and are committed to bringing this innovative therapy to COPD patients in the U.S. as quickly as possible.”
More articles on supply chain:
Pharma spent $78M on lobbying so far this year: 4 statistics
Dr. Scott Gottlieb talks drug price strategies, FDA hiring freeze: 4 takeaways
Sawai Pharma to acquire Upsher-Smith’s generic drug unit for $1B
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
